Aurora, a Leading Global Medical Cannabis Company, Attends the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB), a leading global medical cannabis company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York City. CFO Simona King will conduct one-on-one investor meetings from September 8-10, 2025.

The presentation will focus on Aurora's strategic investments and plans for delivering long-term shareholder value in the medical cannabis industry. Investors can access the presentation via webcast through Aurora's investor relations website, with replay available for 90 days.

NASDAQ | TSX: ACB

EDMONTON, AB, Sept. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will be attending the H.C. Wainwright 27th Annual Global Investment Conference in New York City, NY. Simona King, Chief Financial Officer at Aurora, will conduct one-on-one meetings with investors throughout the conference on September 8-10, 2025.

Simona has prepared a presentation highlighting Aurora's strategic investments and how the company plans to continue delivering long-term shareholder value in the evolving medical cannabis industry.

To listen to this presentation, please follow the weblink HERE, which has also been posted to the Company's "Investor Info" section at https://www.auroramj.com/investors/ under "Events". A replay of the presentation will be available using the same link for approximately 90 days.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur.  Forward-looking statements in this news release include, but are not limited to, those regarding the Company's attendance at the H.C. Wainwright 27^th Annual Global Investment Conference.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-a-leading-global-medical-cannabis-company-attends-the-hc-wainwright-27th-annual-global-investment-conference-302547824.html

SOURCE Aurora Cannabis Inc.

FAQ

When is Aurora Cannabis (ACB) presenting at the H.C. Wainwright Conference 2025?

Aurora Cannabis will be conducting one-on-one meetings with investors from September 8-10, 2025 at the conference in New York City.

Who will represent Aurora Cannabis (ACB) at the H.C. Wainwright Conference?

Simona King, Aurora Cannabis's Chief Financial Officer, will represent the company and conduct one-on-one meetings with investors.

How can investors access Aurora Cannabis's (ACB) H.C. Wainwright Conference presentation?

Investors can access the presentation through a webcast link available on Aurora's investor relations website at auroramj.com/investors under the 'Events' section. A replay will be available for 90 days.

What topics will Aurora Cannabis (ACB) discuss at the H.C. Wainwright Conference?

The presentation will focus on Aurora's strategic investments and plans for delivering long-term shareholder value in the medical cannabis industry.